BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Valeant Pharmaceuticals International (VRX) Buys-Out Rights to All Current and Future Income and Milestone Obligations From Former Dow Pharmaceutical Sciences (JOBS) Stockholders for $115M


9/29/2009 9:15:17 AM

ALISO VIEJO, Calif., Sept. 29 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International today announced that, for a one-time payment of $115 million, it has agreed to buy-out income rights associated with all out-licensed and pipeline products and the former stockholders of Dow Pharmaceutical Sciences, Inc. have agreed to release Valeant from up to $235 million in milestone obligations they could have received upon successful commercialization of Dow pipeline compounds currently under development. Income rights to the 1% clindamycin and 5% benzoyl peroxide gel Abbreviated New Drug Application were excluded from the acquisition of Dow by Valeant in December 2008.

"We believe this transaction creates significant short-term and long-term value for Valeant shareholders," stated J. Michael Pearson, chairman and chief executive officer. "In the short-term, we immediately offset the erosion from our ribavirin royalties and in the longer-term, we could avoid considerable future milestone obligations that would be incurred if we successfully commercialize our dermatology compounds acquired from Dow. After reviewing phase II results on three of our dermatology compounds and meeting with the FDA this past summer, we believe these compounds have strong potential for future success. We can now turn our efforts to moving these compounds into phase III studies and continuing to focus on building a strong dermatology franchise."

About Valeant

Valeant Pharmaceuticals International is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including, but not limited to, statements regarding the Dow pipeline currently under development and their impact on future growth and the successful commercialization of our dermatology portfolio. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that phase II results may not be indicative of the success of phase III studies or the commercial success of any products, and other risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)

SOURCE Valeant Pharmaceuticals International



CONTACT: Laurie W. Little of Valeant Pharmaceuticals, +1-949-461-6002,
laurie.little@valeant.com

Web site: http://www.valeant.com/




 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES